- Home
- XENE vs VRDN Comparison
XENE vs VRDN Comparison
Compare XENE & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XENE | VRDN |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.7B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | XENE | VRDN |
|---|---|---|
| Price | $43.74 | $32.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $53.91 | $39.73 |
| AVG Volume (30 Days) | 793.2K | ★ 1.6M |
| Earning Date | 11-03-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,500,000.00 | ★ $70,789,000.00 |
| Revenue This Year | N/A | $26,477.48 |
| Revenue Next Year | N/A | $6.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 23340.07 |
| 52 Week Low | $26.74 | $9.90 |
| 52 Week High | $46.60 | $33.34 |
Technical Indicators
Market Signals| Indicator | XENE | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | 65.96 |
| Support Level | $42.89 | $32.29 |
| Resistance Level | $44.57 | $33.29 |
| Average True Range (ATR) | 1.42 | 1.20 |
| MACD | -0.07 | -0.18 |
| Stochastic Oscillator | 32.63 | 67.54 |
Price Performance
Historical ComparisonAbout XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).